Claims for Patent: 8,168,218

Summary for Patent: 8,168,218

Title:	Delayed release tablet with defined core geometry
Abstract:	A press-coated tablet comprising a core containing an drug substance, and a coating, the core being disposed within the coating such that the coating has a first thickness about an axis A-B and a thickness about an orthogonal axis X-Y, such that the coating about the axis X-Y is thicker than the coating about the axis A-B, and is adapted to provide a lag time of between about 2 to 6 hours during which substantially no drug substance is released.
Inventor(s):	Vergnault; Guy (Kembs Loechle, FR), Grenier; Pascal (Kappelen, FR), Dragan; Christophe (Geispitzen, FR)
Assignee:	Jagotec AG (Muttenz, CH)
Application Number:	10/554,538
Patent Claims:	1. A press-coated tablet comprising a core containing 5 mg of prednisone and a coating around the core, said core being disposed within said coating such that the coating thickness about an axis (X-Y) is thicker than the coating about an axis (A-B) orthogonal to (X-Y), wherein the thickness of the coating about the axis (X-Y) is selected such that the coating ruptures upon immersion in an aqueous medium after a period of between about 2 to about 6 hours to release the drug, wherein coating material about the (X-Y) axis is relatively less dense than the coating material disposed about the (A-B) axis and the coating material about the (X-Y) axis is more permissive towards ingress of aqueous media than the coating material disposed about the axis (A-B), and wherein the axis (A-B) is the axis of the direction of movement of the punch used in the press-coating of the tablet: said tablet comprising the following ingredients Core of 5 mg prednisone tablet: Prednisone 8.33% as a percentage by weight in said core; Lactose monohydrate 64.47% as a percentage by weight in said core; Povidone 6.67% as a percentage by weight in said core; Croscarmellose sodium 18.33% as a percentage by weight in said core; Red ferric oxide 0.5% as a percentage by weight in said core; Magnesium stearate Vegetable origin 1.0% as a percentage by weight in said core; Colloidal silicon dioxide 0.5% as a percentage by weight in said core; Coating: Dibasic calcium phosphate dihydrate 50% as a percentage by weight in said coating; Glyceryl behenate 40% as a percentage by weight in said coating; Povidone 8.40% as a percentage by weight in said coating; Yellow ferric oxide 0.1% as a percentage by weight in said coating; Magnesium stearate Vegetable origin 1.0% as a percentage by weight in said coating; Colloidal silicon dioxide 0.5% as a percentage by weight in said coating. 2. The tablet according to claim 1 wherein, upon administration to a patient, the lag time before drug release is 2 to 6 hours. 3. The tablet according to claim 1, said tablet having an in vitro dissolution profile using USP dissolution apparatus No. 2, at a stirring rate of 100 rpm and in a dissolution medium of 500 mL purified water, wherein said dissolution profile comprises a median lag time of about 4 hours with at least 80% of a drug substance being released after 4.5 hours and about 100% of the drug substance being released after 5 hours. 4. The tablet according to claim 1 wherein intra-subject or inter-subject variability in T.sub.max differs by less than +/-20% whether or not a patient is in a fed or a fasted (fed/fasted) state. 5. The tablet according to claim 1 wherein upon administration to a patient the ratio of C.sub.max fed/fasted upon single dosing is 0.7 to 1.43. 6. The tablet according claim 1 wherein upon administration to a patient the ratio of AUC fed/fasted upon single dosing is 0.8 to 1.25. 7. A pharmaceutical package containing a tablet according to claim 1 together with labelling or instructions that the tablet can be taken with or without food. 8. A method of treating arthritic pain, allergies, asthma, Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) by providing to a patient in need of treatment a tablet according to claim 1. 9. A method of preparing a tablet according to claim 1 comprising the steps of: (a) forming a first granulate-containing coating material; (b) forming a core comprising a second granulate-containing core material; and (c) press coating the first granulate-containing coating material around the core.